There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Humacyte (HUMA) and Tectonic Therapeutic (TECX) with bullish sentiments.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Humacyte (HUMA)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Humacyte today and set a price target of $1.50. The company’s shares closed last Wednesday at $1.34.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of 2.3% and a 46.2% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humacyte with a $2.50 average price target, a 78.6% upside from current levels. In a report issued on June 1, Benchmark Co. also maintained a Buy rating on the stock with a $2.00 price target.
